Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 280

1.

Epidemiology of respiratory syncytial virus infection in infants born at less than thirty-five weeks of gestational age.

Park HW, Lee BS, Kim AR, Yoon HS, Kim BI, Song ES, Kim WT, Lim J, Kim S, Jin HS, Byun S, Chee DH, Kim KS.

Pediatr Infect Dis J. 2012 Aug;31(8):e99-104. doi: 10.1097/INF.0b013e318257f619.

PMID:
22531234
2.
3.

Effect of palivizumab prophylaxis in decreasing respiratory syncytial virus hospitalizations in premature infants.

Pedraz C, Carbonell-Estrany X, Figueras-Aloy J, Quero J; IRIS Study Group.

Pediatr Infect Dis J. 2003 Sep;22(9):823-7.

PMID:
14506376
4.

Respiratory syncytial virus and premature infants born at 32 weeks' gestation or earlier: hospitalization and economic implications of prophylaxis.

Stevens TP, Sinkin RA, Hall CB, Maniscalco WM, McConnochie KM.

Arch Pediatr Adolesc Med. 2000 Jan;154(1):55-61.

PMID:
10632251
5.
7.

FLIP-2 Study: risk factors linked to respiratory syncytial virus infection requiring hospitalization in premature infants born in Spain at a gestational age of 32 to 35 weeks.

Figueras-Aloy J, Carbonell-Estrany X, Quero-Jiménez J, Fernández-Colomer B, Guzmán-Cabañas J, Echaniz-Urcelay I, Doménech-Martínez E; IRIS Study Group.

Pediatr Infect Dis J. 2008 Sep;27(9):788-93. doi: 10.1097/INF.0b013e3181710990.

PMID:
18664927
8.

Incidence of respiratory syncytial virus-related hospitalizations in high-risk children: follow-up of a national cohort of infants treated with Palivizumab as RSV prophylaxis.

Lacaze-Masmonteil T, Rozé JC, Fauroux B; French Pediatricians' Group of Sunagis Patients' Name-Based Programs.

Pediatr Pulmonol. 2002 Sep;34(3):181-8.

PMID:
12203846
10.

Respiratory syncytial virus prophylaxis in preterm infants: a cost-effectiveness study from Turkey.

Oncel MY, Mutlu B, Kavurt S, Baş AY, Demirel N, Akyol M, Erdeve O, Dilmen U.

Turk J Pediatr. 2012 Jul-Aug;54(4):344-51.

PMID:
23692714
11.

Admission to the intensive care unit for respiratory syncytial virus bronchiolitis: a national survey before palivizumab use.

Prais D, Schonfeld T, Amir J; Israeli Respiratory Syncytial Virus Monitoring Group.

Pediatrics. 2003 Sep;112(3 Pt 1):548-52.

PMID:
12949282
12.

The Pediatric Investigators Collaborative Network on Infections in Canada study of predictors of hospitalization for respiratory syncytial virus infection for infants born at 33 through 35 completed weeks of gestation.

Law BJ, Langley JM, Allen U, Paes B, Lee DS, Mitchell I, Sampalis J, Walti H, Robinson J, O'Brien K, Majaesic C, Caouette G, Frenette L, Le Saux N, Simmons B, Moisiuk S, Sankaran K, Ojah C, Singh AJ, Lebel MH, Bacheyie GS, Onyett H, Michaliszyn A, Manzi P, Parison D.

Pediatr Infect Dis J. 2004 Sep;23(9):806-14.

PMID:
15361717
13.

Rehospitalization for respiratory syncytial virus among premature infants.

Joffe S, Escobar GJ, Black SB, Armstrong MA, Lieu TA.

Pediatrics. 1999 Oct;104(4 Pt 1):894-9.

PMID:
10506231
14.

A meta-analysis of the effect of antibody therapy for the prevention of severe respiratory syncytial virus infection.

Morris SK, Dzolganovski B, Beyene J, Sung L.

BMC Infect Dis. 2009 Jul 5;9:106. doi: 10.1186/1471-2334-9-106.

15.

Guidelines for palivizumab prophylaxis: are they based on infant's risk of hospitalization for respiratory syncytial viral disease?

Elhassan NO, Stevens TP, Sorbero ME, Dick AW, Guillet R, Hall CB.

Pediatr Infect Dis J. 2003 Nov;22(11):939-43.

PMID:
14614363
16.

Palivizumab prophylaxis and hospitalization for respiratory syncytial virus disease in the Stockholm infant population, 1999 through 2002.

Henckel E, Luthander J, Berggren E, Kapadia H, Naver L, Norman M, Bennet R, Eriksson M.

Pediatr Infect Dis J. 2004 Jan;23(1):27-31.

PMID:
14743042
17.

Risk-Scoring Tool for respiratory syncytial virus prophylaxis in premature infants born at 33-35 completed weeks' gestational age in Canada.

Paes B, Steele S, Janes M, Pinelli J.

Curr Med Res Opin. 2009 Jul;25(7):1585-91. doi: 10.1185/03007990902929112.

PMID:
19469698
18.

Hospital admission of high risk infants for respiratory syncytial virus infection: implications for palivizumab prophylaxis.

Heikkinen T, Valkonen H, Lehtonen L, Vainionpää R, Ruuskanen O.

Arch Dis Child Fetal Neonatal Ed. 2005 Jan;90(1):F64-8.

19.

The cost-effectiveness of palivizumab for respiratory syncytial virus prophylaxis in premature infants with a gestational age of 32-35 weeks: a Canadian-based analysis .

Lanctôt KL, Masoud ST, Paes BA, Tarride JE, Chiu A, Hui C, Francis PL, Oh PI.

Curr Med Res Opin. 2008 Nov;24(11):3223-37. doi: 10.1185/03007990802484234 . Epub 2008 Oct 16.

PMID:
18928643
20.

Rehospitalization because of respiratory syncytial virus infection in premature infants younger than 33 weeks of gestation: a prospective study. IRIS Study Group.

Carbonell-Estrany X, Quero J, Bustos G, Cotero A, Doménech E, Figueras-Aloy J, Fraga JM, García LG, García-Alix A, Del Río MG, Krauel X, Sastre JB, Narbona E, Roqués V, Hernández SS, Zapatero M.

Pediatr Infect Dis J. 2000 Jul;19(7):592-7.

PMID:
10917214

Supplemental Content

Support Center